Clinical Scorecard: Development of a Prognostic Nomogram for Cervical Cancer Patients Infected with Hepatitis B Virus: A Retrospective Analysis

At a Glance

Key Highlights

• Established a nomogram for predicting overall survival in HBsAg-positive cervical cancer patients.
• Identified independent prognostic factors including tumor stage and baseline serum AST levels.
• Nomogram showed higher predictive accuracy (C-index 0.817) compared to FIGO staging system (C-index 0.700).
• High-risk group based on nomogram experienced significantly poorer overall survival (P < 0.001).
• Further validation of the nomogram is required before clinical application.

Guideline-Based Recommendations

Diagnosis

• Histological confirmation of cervical squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma.

Management

• Consider antiviral therapy for patients with chronic HBV infection.

Monitoring & Follow-up

• Regular follow-up with comprehensive clinical information and LFIs.

Risks

• Risk of HBV reactivation during chemotherapy.

Patient & Prescribing Data

149 HBsAg-positive cervical cancer patients treated at Yunnan Cancer Hospital.

Incorporation of clinical characteristics and antiviral treatment in prognostic evaluation.

Clinical Best Practices

• Utilize nomograms for individualized prognostic assessments in HBsAg-positive cervical cancer patients.
• Monitor liver function indicators in patients undergoing treatment.

Related Resources & Content

• International Federation of Gynecology and Obstetrics (FIGO) staging system